{
     "PMID": "10924924",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20001012",
     "LR": "20161124",
     "IS": "0014-2999 (Print) 0014-2999 (Linking)",
     "VI": "401",
     "IP": "2",
     "DP": "2000 Aug 4",
     "TI": "Cannabinoid CB(1) receptor agonists increase rat cortical and hippocampal acetylcholine release in vivo.",
     "PG": "179-85",
     "AB": "Intravenous administration of the cannabinoid CB(1) receptor agonists (R-(+)-[2, 3-Dihydro-5-methyl-3[morpholinyl)methyl]-pyrrolo[1,2,3-de]-1, 4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate), WIN 55,212-2 (10, 37.5, 75 and 150 microg/kg), and ((6aR)-trans-3-(1, 1-Dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6, 6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol), HU 210 (1 and 4 microg/kg) dose-dependently increased acetylcholine release in dialysates from the prefrontal cortex and the hippocampus of freely moving rats. Administration of the cannabinoid receptor antagonist [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3 carboxamide]HCl, SR 141716A, at a dose that per se did not affect basal acetylcholine release (2. 5 microg/kg), prevented the increase of acetylcholine release by WIN 55,212-2 (150 microg/kg i.v.) or by HU 210 (4 microg/kg i.v.) in both areas. These data demonstrate that, at low i.v. doses, the synthetic cannabinoid CB(1) receptor agonists, WIN 55,212-2 and HU 210 stimulate cortical and hippocampal acetylcholine release.",
     "FAU": [
          "Acquas, E",
          "Pisanu, A",
          "Marrocu, P",
          "Di Chiara, G"
     ],
     "AU": [
          "Acquas E",
          "Pisanu A",
          "Marrocu P",
          "Di Chiara G"
     ],
     "AD": "Department of Toxicology, University of Cagliari and Centre for Neuropharmacology, CNR, V.le A. Diaz, 182, 09126, Cagliari, Italy.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "Netherlands",
     "TA": "Eur J Pharmacol",
     "JT": "European journal of pharmacology",
     "JID": "1254354",
     "RN": [
          "0 (Benzoxazines)",
          "0 (Morpholines)",
          "0 (Naphthalenes)",
          "0 (Piperidines)",
          "0 (Pyrazoles)",
          "0 (Receptors, Cannabinoid)",
          "0 (Receptors, Drug)",
          "5H31GI9502 (Win 55212-2)",
          "7J8897W37S (Dronabinol)",
          "N9YNS0M02X (Acetylcholine)",
          "R6VT8U5372 (HU 211)",
          "RML78EN3XE (rimonabant)"
     ],
     "SB": "IM",
     "MH": [
          "Acetylcholine/*secretion",
          "Animals",
          "Behavior, Animal/drug effects",
          "Benzoxazines",
          "Dose-Response Relationship, Drug",
          "Dronabinol/analogs & derivatives/pharmacology",
          "Hippocampus/*drug effects/metabolism",
          "Male",
          "Microdialysis",
          "Morpholines/pharmacology",
          "Naphthalenes/pharmacology",
          "Piperidines/pharmacology",
          "Prefrontal Cortex/*drug effects/metabolism",
          "Pyrazoles/pharmacology",
          "Rats",
          "Rats, Sprague-Dawley",
          "Receptors, Cannabinoid",
          "Receptors, Drug/*agonists/antagonists & inhibitors"
     ],
     "EDAT": "2000/08/05 11:00",
     "MHDA": "2000/10/14 11:01",
     "CRDT": [
          "2000/08/05 11:00"
     ],
     "PHST": [
          "2000/08/05 11:00 [pubmed]",
          "2000/10/14 11:01 [medline]",
          "2000/08/05 11:00 [entrez]"
     ],
     "AID": [
          "S0014-2999(00)00403-9 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Eur J Pharmacol. 2000 Aug 4;401(2):179-85.",
     "term": "hippocampus"
}